LSD Microdosing Study Finds ‘No Residual Effects’ on Mood or Cognition
ResearchAnother study concludes with results challenging the increasingly popular narrative that microdosing psychedelics improves mood and cognitive function.
Is ‘The Trip’ Essential to The Psychedelic Experience?
ResearchBiology and experience are tough to separate, but some researchers are exploring the possibility of non-hallucinogenic psychedelics as a mental health treatment. This begs the question: what do we lose, and what do we gain when we take the trip out of the psychedelic experience?
Psychedelics Can Change Your View on the Nature of Reality
ResearchA recent study has found that psychedelics can fundamentally change your core beliefs about the nature of fate, reality, and consciousness.
Texas Further Embraces Psychedelics with Launch of Center for Psychedelic Research and Therapy
ResearchResearch will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD.
Can Psychedelics Treat Alzheimer’s Disease?
Research, TreatmentSince substances such as LSD and psilocybin have powerful anti-inflammatory properties, researchers argue that the microbiological action of psychedelics may therefore help fight brain-based symptoms in early Alzheimer’s patients.
FDA Green Lights Tryp Therapeutics’ Psilocybin Study on Binge Eating Disorder
ResearchThe pharmaceutical company developing psilocybin-based compounds for diseases with unmet medical needs estimates a $2.9 billion market potential for such a treatment.
Understanding HPPD to Prioritize Harm Reduction of a Very Real Psychedelic Risk
Research“HPPD is precisely the kind of risk that could fall through the cracks," says journalist Ed Prideaux, who suffers from the condition and advocates for more research.
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
ResearchChief Medical Officer Guy Goodwin calls study "a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy."
Non-Hallucinogenic DMT? Psilera Bioscience Reports Progress on ‘Well-Tolerated’ Derivative
Business, ResearchFurther in vivo studies with PSIL-002 will evaluate its antidepressant, anxiolytic, and anti-addictive properties, specifically targeting alcohol consumption.
You Can Make ‘Bad Trips’ Good with Storytelling, Psychedelics Study Shows
ResearchEvidence supports the idea that the possibly unpleasant nature of the psychedelic experience is an integral part of its therapeutic benefits.